Details:
Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AdimFlu-S
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Clover Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 19, 2023
Details:
The results from study served as basis for immunobriding that gives MVC-COV1901 vaccine's Emergency Use Authorization in Taiwan and can support the advancement in subsequent developments.MVC-COV1901 vaccine involves molecular modifications to S-2P pre-fusion spike protein.
Lead Product(s): Recombinant S-2P antigen,CpG 1018,Aluminum hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: MVC-COV1901
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.
Lead Product(s): Nemonoxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Taigexyn
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Luminarie
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 30, 2020